Catalent, Pure MHC Partner - - BioPharm International

ADVERTISEMENT

Catalent, Pure MHC Partner



Untitled Document

Pure MHC, a provider of MHC-based diagnostics and therapeutics, and Catalent have signed a product-development agreement under which Catalent will develop a humanized version of Pure MHC’s proprietary RL21A antibody, an anticancer agent, and engineer a cell line to express the antibody using Catalent’s GPExO, technology. Catalent will subsequently produce purified monoclonal antibodies to support Pure MHC’s preclinical development in preparation for clinical trials with humanized RL21A. MHC (major histocompatibility complex) is a group of genes that code proteins found on the surface of cells that help the immune system recognize foreign substances.

Pure MHC has developed a suite of MHC/ligand targets that recognize cancerous cells in addition to producing monoclonal antibodies for these distinct MHC/ligand cancer targets. 

Source: Catalent

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
USP Center in Ghana Receives International Lab Accreditation
August 15, 2014
USP Awards Analytical Research
August 15, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
Author Guidelines

Click here